In vitro activity of cefodizime (HR-221)
- 1 October 1982
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 22 (4) , 715-718
- https://doi.org/10.1128/aac.22.4.715
Abstract
The in vitro activity of cefodizime (HR-221), a new cephalosporin antibiotic, was compared with the activities of selected antimicrobial agents against a broad spectrum of aerobic bacteria. Cefodizime concentrations of 2 micrograms/ml inhibited about 90% of Enterobacteriaceae studied. Serratia marcescens required 8 micrograms/ml to inhibit 90% of strains. Among gram-positive cocci, 50% of strains were inhibited by 2 micrograms/ml of cefodizime (including methicillin-resistant Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus faecalis, and penicillin-resistant Streptococcus pneumoniae). Pseudomonas aeruginosa was less susceptible to cefodizime. Cefotaxime, an antibiotic closely related to cefodizime structurally, was about fourfold more active.Keywords
This publication has 3 references indexed in Scilit:
- Comparative in Vitro Activities of Cefmenoxime (SCE-1365) and Newer Cephalosporin Derivatives of Clinical UtilityAntimicrobial Agents and Chemotherapy, 1982
- In vitro antimicrobial activity evaluation of cefodizime (HR221), a new semisynthetic cephalosporinAntimicrobial Agents and Chemotherapy, 1981
- Beta-lactamase stability and antibacterial activity of cefmenoxime (SCE-1365), a novel cephalosporinAntimicrobial Agents and Chemotherapy, 1981